Conspectus
Nanotechnology is revolutionizing
human medicine. Nanoparticles
(NPs) are currently used for treating various cancers, for developing
vaccines, and for imaging, and other promises offered by NPs might
come true soon. Due to the interplay between NPs and proteins, there
is more and more evidence supporting the role of NPs for treating
amyloid-based diseases. NPs can induce some conformational changes
of the adsorbed protein molecules via various molecular interactions,
leading to inhibition of aggregation and fibrillation of several and
different amyloid proteins. Though an in depth understanding of such
interactions between NPs and amyloid structures is still lacking,
the inhibition of protein aggregation by NPs represents a new generation
of innovative and effective medicines to combat metabolic diseases
such as type 2 diabetes (T2D). Here, we lay out advances made in the
field of T2D notably for optimizing protein aggregation inhibition
strategies. This Account covers discussions about the current understanding
of β-cells, the insulin producing cells within the pancreas,
under diabetic conditions, notably increased glucose and fatty acid
levels, and the implication of these conditions on the formation of
human islet amyloid polypeptide (hIAPP) amylin oligomers and aggregates.
Owing to the great potential of carbon nanostructures to interfere
with protein aggregation, an important part of this Account will be
devoted to the state of the art of therapeutic options in the form
of emerging nanomaterials-based amyloidosis inhibitors. Our group
has recently made some substantial progress in this regard by investigating
the impact of glucose and fatty acid concentrations on hIAPP aggregation
and β-cell toxicity. Furthermore, the great potential of carbon
nanocolloids in reversing hIAPP aggregation under diabetic conditions
will be highlighted as the approach has been validated on β-cell
cultures from rats. We hope that this Account will evoke new ideas
and concepts in this regard. We give some lead references below on
pancreatic β-cell aspects and carbon quantum dots for managing
diabetics and nanomedicine related aspects, a topic of interest in
our laboratory.